
Sign up to save your podcasts
Or
The United States stands at a pivotal juncture in eliminating HIV. Despite recent advancements, including the development of an effective new form of pre-exposure prophylaxis (PrEP), an uncertain future marked by cuts to Medicaid and research hurdles threatens to undo the country’s progress. In this episode: Jeremiah Johnson, Executive Director of PrEP4All, sheds light on the urgent need for equitable access to PrEP and what’s at stake if we fail to scale up initiatives to test, prevent, and treat HIV.
Guest:Jeremiah Johnson is the Executive Director of PrEP4All—an organization that seeks to prevent the spread of HIV by identifying data-driven policy solutions to increase access to PrEP.
Host:Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland’s Health Department.
Show links and related content:Trump’s Policies Could Undermine the Fight to End America’s HIV Epidemic—Tradeoffs
FDA approves Gilead’s twice-yearly HIV prevention injection, offering a powerful and convenient new option—CNBC
Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic—Journal of Law, Medicine & Ethics
A National PrEP Program to End the Nation’s HIV Epidemic—Public Health On Call (April 2022)
Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel.
Contact us:Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website.
Follow us:@PublicHealthPod on Bluesky
@JohnsHopkinsSPH on Instagram
@JohnsHopkinsSPH on Facebook
@PublicHealthOnCall on YouTube
Here's our RSS feed
Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.
4.6
609609 ratings
The United States stands at a pivotal juncture in eliminating HIV. Despite recent advancements, including the development of an effective new form of pre-exposure prophylaxis (PrEP), an uncertain future marked by cuts to Medicaid and research hurdles threatens to undo the country’s progress. In this episode: Jeremiah Johnson, Executive Director of PrEP4All, sheds light on the urgent need for equitable access to PrEP and what’s at stake if we fail to scale up initiatives to test, prevent, and treat HIV.
Guest:Jeremiah Johnson is the Executive Director of PrEP4All—an organization that seeks to prevent the spread of HIV by identifying data-driven policy solutions to increase access to PrEP.
Host:Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland’s Health Department.
Show links and related content:Trump’s Policies Could Undermine the Fight to End America’s HIV Epidemic—Tradeoffs
FDA approves Gilead’s twice-yearly HIV prevention injection, offering a powerful and convenient new option—CNBC
Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic—Journal of Law, Medicine & Ethics
A National PrEP Program to End the Nation’s HIV Epidemic—Public Health On Call (April 2022)
Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel.
Contact us:Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website.
Follow us:@PublicHealthPod on Bluesky
@JohnsHopkinsSPH on Instagram
@JohnsHopkinsSPH on Facebook
@PublicHealthOnCall on YouTube
Here's our RSS feed
Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.
5 Listeners
2,050 Listeners
40 Listeners
25 Listeners
25,773 Listeners
5 Listeners
3,320 Listeners
110,802 Listeners
55,980 Listeners
90 Listeners
479 Listeners
9 Listeners
46 Listeners
1,082 Listeners
16 Listeners
4 Listeners
4,485 Listeners
390 Listeners
6,206 Listeners
24 Listeners
5,986 Listeners
15,457 Listeners
82 Listeners
82 Listeners